Articles with public access mandates - Pedro Luiz Serrano Uson JuniorLearn more
Not available anywhere: 2
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
PLS Uson Junior, TT DeLeon, JM Bogenberger, RK Pai, HE Kosiorek, ...
Digestive diseases and sciences, 1-9, 2022
Mandates: US National Institutes of Health
Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications
LA Kankeu Fonkoua, PL Serrano Uson Junior, K Mody, A Mahipal, ...
Expert opinion on therapeutic targets 26 (1), 79-92, 2022
Mandates: US National Institutes of Health
Available somewhere: 8
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis
MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ...
JAMA oncology, e204930-e204930, 2020
Mandates: US National Institutes of Health
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ...
Annals of Oncology 33 (12), 1269-1283, 2022
Mandates: US Department of Defense, US National Institutes of Health, V Foundation, USA
Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study
PLS Uson Jr, NJ Samadder, D Riegert-Johnson, L Boardman, MJ Borad, ...
Clinical and translational gastroenterology 12 (10), e00414, 2021
Mandates: US National Institutes of Health
Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma
G Botrus, H Kosirorek, MB Sonbol, Y Kusne, PLSU Junior, MJ Borad, ...
The oncologist, 2021
Mandates: US National Institutes of Health
Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
PLSU Junior, U Majeed, G Botrus, MB Sonbol, D Ahn, J Starr, J Jones, ...
JCO Precision Oncology, 2022
Mandates: US National Institutes of Health
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
BM Nagalo, Y Zhou, EJ Loeuillard, C Dumbauld, O Barro, NM Elliott, ...
Hepatology 77 (6), 1943-1957, 2023
Mandates: US Department of Defense, US National Institutes of Health
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
M Arora, JM Bogenberger, AM Abdelrahman, J Yonkus, R Alva‐Ruiz, ...
Hepatology 75 (1), 43-58, 2022
Mandates: US National Institutes of Health
A Pilot Study of Ponatinib in Patients With FGFR-Altered Advanced Cholangiocarcinoma
DH Ahn, PLSU Junior, P Masci, H Kosiorek, TR Halfdanarson, K Mody, ...
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program